Welcome to our dedicated page for Vitrolife news (Ticker: VTRLY), a resource for investors and traders seeking the latest updates and insights on Vitrolife stock.
The VTRLY news page tracks company communications and market-facing updates related to Vitrolife AB (publ), a biotechnology group active in reproductive health. Investors can use this feed to follow how the Vitrolife Group reports on its regional and product group performance, as well as strategic and financing developments that may influence the underlying business.
Vitrolife AB (publ) regularly publishes interim reports that detail sales in local currencies across EMEA, Americas and APAC, and across its Consumables, Technologies and Genetics product groups. These reports discuss organic growth excluding discontinued business, currency effects on sales and margins, gross margin levels, EBITDA, operating cash flow and net income. News items linked to these reports often include conference call invitations, where management presents the results and answers questions from investors, analysts and financial media.
The news flow also covers strategic initiatives and organisational changes. For example, Vitrolife AB (publ) has announced that it became a leading investor in AutoIVF, an early-stage MedTech company focused on making IVF more accessible, affordable and efficient through its OvaReady™ technology. The company has also communicated changes to its Executive Management Team, including the introduction of a SVP Innovation role to oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management and Market Access.
Governance and capital structure events appear in the form of Annual General Meeting notices and reports, which describe proposed and approved dividends, Board elections, auditor re-elections, share issue and share repurchase authorisations and share-based incentive programs. Financing news includes announcements such as the renewal and signing of a loan agreement comprising a term loan and revolving credit facility backed by Nordic banks.
By reviewing the VTRLY news feed, readers can follow how Vitrolife AB (publ) communicates on financial performance, IVF-related strategic investments, executive appointments, governance decisions and loan facilities. This makes the page a useful reference for anyone monitoring the company’s publicly disclosed developments over time.
Vitrolife AB announces the expansion of its genomic testing kits distribution to the Asia Pacific region (excluding China). This move follows the partnership with Illumina and requires a payment of USD 3 million for expanded rights. The commercial launch of EmbryoMap occurred in Q2 of this year, expected to generate over SEK 50 million in revenue in 2022, positively impacting earnings per share.
Vitrolife AB reported a strong financial performance for the third quarter of 2021, with sales reaching SEK 406 million, a 27% increase year-over-year. EBITDA rose to SEK 162 million, yielding a 40% margin. The company also announced the acquisition of Igenomix for EUR 1.25 billion, financed partially through a directed share issue of SEK 3.6 billion. For January to September 2021, total sales were SEK 1,167 million, up 35%, and net income increased to SEK 310 million. A non-cash share issue of SEK 6.4 billion was also approved to help fund this acquisition.
Vitrolife AB has appointed Patrik Tolf as the new CFO, effective January 1, 2022. Tolf, currently serving as interim CFO at Karolinska University Hospital, has a strong background with previous roles in finance at Volvo Car Group and Saab AB. He replaces Mikael Engblom, who will remain in the position until Tolf's start date. CEO Thomas Axelsson expressed confidence in Tolf's operational and strategic expertise to enhance the company’s growth journey.
At Vitrolife's Extraordinary General Meeting on October 20, 2021, decisions were made to facilitate the acquisition of Igenomix through a non-cash consideration issue. Additionally, Vesa Koskinen was elected as a new board member, resulting in an increase in board remuneration due to the expanded membership. These decisions are contingent upon the successful completion of the non-cash issue.
Vitrolife invites stakeholders to join a conference call on October 29, 2021, at 10:00 a.m. CET to discuss its interim report for the period of January to September 2021. The call will be held in English, with registration recommended 10-15 minutes prior. Participants can dial in using the provided Swedish or international numbers. The interim report will be released at 8:00 CET on the same day, with presentation materials accessible on the company’s website.
On October 12, 2021, Vitrolife announced the appointment of its election committee members for the 2022 Annual General Meeting. The committee will include Niels Jacobsen from William Demant Invest A/S, Patrik Tigerschiöld from Bure Equity AB, and Wendy Wang from Morgan Stanley Investment Management Inc., with Jón Sigurdsson serving as Chairman. The Annual General Meeting is scheduled for April 27, 2022, in Gothenburg. Shareholders wishing to propose agenda items must submit requests to the Board seven weeks prior to the meeting.
Vitrolife AB has announced an Extraordinary General Meeting (EGM) for shareholders on October 20, 2021, with advance postal voting required. Shareholders must be registered by October 12, 2021, to participate. Key proposals include expanding the Board to six members, an increase in Board remuneration to SEK 2,440,000, and the election of Vesa Koskinen as a new Board member. Additionally, a non-cash issue of shares related to the acquisition of Igenomix will be proposed for approval.
Vitrolife's CFO, Mikael Engblom, has resigned, effective immediately. Engblom, who has served in this role since 2011, will remain until a replacement is found. During his tenure, he significantly contributed to the company's transformation into a market leader in reproductive health, as noted by CEO Thomas Axelsson. Engblom expressed a desire for new challenges after ten years with the company. A recruitment process for a new CFO will commence shortly.
On July 30, 2021, Vitrolife AB announced the issuance of 9,645,303 new shares following a board decision on July 8, 2021. With this issuance, the total number of shares and votes for Vitrolife AB has increased to 118,195,878 as of the announcement date.
Vitrolife AB has completed its share buyback program, repurchasing a total of 52,568 shares from July 15-16, 2021. This initiative was designed to meet obligations related to the long-term incentive program LTIP2021. The buyback was executed under the Market Abuse Regulation and concluded with a total transaction value of SEK 22,822,482 across the two days. Following this buyback, Vitrolife holds 52,568 shares out of a total of 118,195,878 shares outstanding.